Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know
06:10am, Thursday, 01'st Jul 2021
The sample size was small, but the results were impressive.
Vir Biotech's HBV Candidates Show Positive Safety Profiles
03:02pm, Friday, 25'th Jun 2021
Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents –
Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death
10:31am, Tuesday, 22'nd Jun 2021
Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
11:41am, Monday, 21'st Jun 2021
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients
Vir, GSK say new data confirms their COVID-19 treatment can reduce hospitalization and death
07:28am, Monday, 21'st Jun 2021
Shares of Vir Biotechnology Inc. gained 1.4% in premarket trading on Monday after the company said the COVID-19 antibody treatment it developed with GlaxoSmithKline cut the risk of hospitalization and
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
07:06am, Monday, 21'st Jun 2021
– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progre
3 Top Biotech Picks for June
06:00am, Saturday, 19'th Jun 2021
Coronavirus players may deliver strong returns well into the future.
Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
04:05pm, Wednesday, 02'nd Jun 2021
SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat
15 Words From Vir Biotechnology's CEO May Mean Market Dominance
06:00am, Wednesday, 02'nd Jun 2021
Vir's antibody treatment is addressing one of the biggest COVID challenges.
FDA approves Vir Biotechnology antibody drug for emergencies
02:46pm, Monday, 31'st May 2021
George Scangos, President and CEO of Vir Biotechnology, joined Yahoo Finance's Julia LaRoche and Adam Shapiro to discuss the latest on the company's COVID-19 antibody treatment. Watch the 2021 Berkshi
The FDA authorized the third monoclonal antibody treatment. Here's why Vir and GSK say the U.S. still needs COVID-19 therapies
12:34pm, Thursday, 27'th May 2021
There are now three antibody-based treatments available in the U.S. to treat adults and teens with mild or moderate forms of COVID-19, though all require intravenous infusions and are not the kind of
Vir Biotechnology gains 10% after receiving EUA for its COVID-19 treatment
10:07am, Thursday, 27'th May 2021
Vir Biotechnology Inc (NASDAQ: VIR) shares jumped roughly 10% in after-hours trading on Wednesday as the company received emergency use authorisation for its COVID-19 drug from the U.S Food and Drug A
GlaxoSmithKline and Vir win FDA emergency authorization for COVID antibody treatment in adults and children
06:29am, Thursday, 27'th May 2021
GlaxoSmithKline plc and Vir Biotechnology Inc. said the U.S. Food and Drug Administration has granted emergency use authorization to its single-dose monoclonal antibody treatment sotrovimab in mild-to
– Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE
